[Therapy of toxoplasmosis].
D006801:Humans; D011739:Pyrimethamine / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D014123:Toxoplasmosis / Q000188:drug therapy*; D014125:Toxoplasmosis, Congenital / Q000517:prevention & control; D015002:Yeast, Dried / Q000627:therapeutic use
D013449:Sulfonamides; D011739:Pyrimethamine
Therapie der Toxoplasmose.